Development of capture assays for different modifications of human low-density lipoprotein

Clinical and Diagnostic Laboratory Immunology

Volumn 12, Issue 1, 2005, Pages 68-75

  Virella, Gabriel ^a   Brooks Derrick, M ^a,b   Pate, Virginia ^a,b   Chassereau, Charlyne ^a,b   Thorpe, Suzanne R ^c   Lopes Virella, Maria F ^b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^c UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ANTIBODY; ANTISERUM; APOLIPOPROTEIN B; COPPER; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN;

ANTIBODY AFFINITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ARTICLE; COMPLEX FORMATION; GAS CHROMATOGRAPHY; HUMAN; IMMUNIZATION; LIPOPROTEIN BLOOD LEVEL; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN MODIFICATION;

ANIMALS; ANTIGEN-ANTIBODY COMPLEX; COPPER; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LIPOPROTEINS, LDL; LYSINE; MALONDIALDEHYDE; RABBITS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 12544254213     PISSN: 1071412X     EISSN: None     Source Type: Journal    
DOI: 10.1128/CDLI.12.1.68-75.2005     Document Type: Article

References (33)

1. Atchley, D. H., M. F. Lopes-Virella, D. Zheng, and G. Virella. 2002. Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy. Diabetologia 45:1562-1571.
2. Bentzen, C. L., K. J. Acuff, B. Marechal, M. A. Rosenthal, and M. E. Volk. 1982. Direct determination of lipoprotein cholesterol distribution with micro-scale affinity chromatography columns. Clin. Chem. 28:1451-1456.
3. Ehara, S., M. Ueda, T. Naruko, K. Haze, A. Itoh, M. Otsuka, R. Komatsu, T. Matsuo, H. Itabe, T. Takano, Y. Tsukamoto, M. Yoshiyama, K. Takeuchi, J. Yoshikawa, and A. E. Becker. 2001. Elevated levels of oxidized low density lipoprotein show a positive relationship with the severity of acute coronary syndromes. Circulation 103:1955-1960.
4. Haberland, M. E., A. M. Fogelman, and P. A. Edwards. 1982. Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc. Natl. Acad. Sci. USA 79:1712-1716.
5. Holvoet, P., J. M. Stassen, J. Van Cleemput, D. Collen, and J. Vanhaecke. 1998. Oxidized low density lipoproteins in patients with transplant-associated coronary artery disease. Arterioscler. Thromb. Vasc. Biol. 18:100-107.
6. Ikeda, K., R. Nagai, T. Sakamoto, H. Sano, T. Araki, N. Sakata, H. Nakayama, M. Yoshida, S. Ueda, and S. Horiuchi. 1998. Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J. Immunol. Methods 215:95-104.
7. Itabe, H., E. Takeshima, H. Iwasaki, J. Kimura, Y. Yoshida, T. Imanaka, and T. Takano. 1994. A monoclonal antibody against oxidized lipoprotein recognizes foam cells in atherosclerotic lesions. Complex formation of oxidized phosphatidylcholines and polypeptides. J. Biol. Chem. 269:15274-15279.
8. Itabe, H., H. Yamamoto, T. Imanaka, K. Shimamura, H. Uchiyama, J. Kimura, T. Sanaka, Y. Hata, and T. Takano. 1996. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J. Lipid Res. 37:45-53.
9. Kotani, K., M. Maekawa, T. Kanno, A. Kondo, N. Toda, and M. Manabe. 1994. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim. Biophys. Acta 1215:121-125.
10. Lopes-Virella, M. F., S. Koskinen, M. Mironova, D. Horne, R. Klein, C. Chasssereau, C. Enockson, and G. Virella. 2000. The preparation of copperoxidized LDL for the measurement of oxidized LDL antibodies by EIA. Atherosclerosis 152:105-113.
11. Lopes-Virella, M. F., and G. Virella. 2003. The role of immune and inflammatory processes in the development of macrovascular disease in diabetes. Front. Biosci. 8:s750-s768.
12. Mironova, M., G. Virella, I. Virella-Lowell, and M. F. Lopes-Virella. 1997. Anti-modified LDL antibodies and LDL-containing immune complexes in IDDM patients and healthy controls. Clin. Immunol. Immunopathol. 85:73-82.
13. Morel, D. W., J. R. Hessler, and G. M. Chisolm. 1983. Low density lipoprotein cytotoxicity induced by free-radical peroxidation of lipid. J. Lipid Res. 24:1070.
14. Nakamura, Y., Y. Horii, T. Nishino, H. Shiiki, Y. Sakaguchi, T. Kagoshima, K. Dohi, Z. Makita, H. Vlassara, and R. Bucala. 1993. Immunochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am. J. Pathol. 143:1649-1656.
15. Onorato, J. M., S. R. Thorpe, and J. W. Baynes. 1998. Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann. N. Y. Acad. Sci. 854:277-290.
16. Palinski, W., M. E. Rosenfeld, S. Ylä-Herttuala, G. C. Gurtner, S. S. Socher, S. W. Butler, S. Parthasarathy, T. E. Carew, D. Steinbergand, and J. L. Witztum. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA 86:1372-1376.
17. Reddy, S., J. Bichler, K. J. Wells-Knecht, S. R. Thorpe, and J. W. Baynes. 1995. N epsilon-(carboxymethyl)lysine is a dominant advanced glycation end product (AGE) antigen in tissue proteins. Biochemistry 34:10872-10878.
18. Requena, J. R., M. X. Fu, M. U. Ahmed, A. J. Jenkins, T. J. Lyons, J. W. Baynes, and S. R, Thorpe. 1997. Quantification of malondialdehyde and 4-hydroxynonenal adducts to lysine residues in native and oxidized human low-density lipoproteins. Biochem. J. 322:317-325.
19. Schmidt, A. M., O. Hori, J. X. Chen, J. F. Li, J. Crandall, J. Zhang, R. Cao, S. D. Yan, J. Brett, and D. Stern. 1995. Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. J. Clin. Investig. 96:1395-1403.
20. Schmidt, A. M., S. D. Yan, J. Brett, R. Mora, R. Nowygrod, and D. Stern. 1993. Regulation of human mononuclear phagocyte migration by cell surface-binding proteins for advanced glycation end products. J. Clin. Investig. 91:2155-2168.
21. Steinberg, D. 1988. Metabolism of lipoproteins and their role in pathogenesis of atherosclerosis. Atheroscler. Rev. 18:1-23.
22. Steinbrecher, U. P. 1987. Oxidation of human low density lipoprotein results in derivatization of lysine residues of apolipoprotein B by lipid peroxide decomposition products. J. Biol. Chem. 262:3603-3608.
23. Steinbrecher, U. P., M. Eisher, J. L. Witztum, and L. K. Curtiss. 1984. Immunogenicity of homologous low density lipoprotein after methylation, ethylation, acetylation, or carbamylation: generation of antibodies specific for derivatized lysine. J. Lipid Res. 25:1109-1116.
24. Takeuchi, M., Z. Makita, K. Yanagisawa, Y. Kameda, and T. Koike. 1999. Detection of noncarboxymethyllysine and carboxymethyllysine advanced glycation end products (AGE) in serum of diabetic patients. Mol. Med. 5:393-405.
25. Takeuchi, M., Y. Yanase, N. Matsuura, S. Yamagishi Si, Y. Kameda, R. Bucala, and Z. Makita. 2001. Immunological detection of a novel advanced glycation end-product. Mol. Med. 7:783-791.
26. Toshima, S., A. Hasegawa, M. Kurabayashi, H. Itabe, T. Takano, J. Sugano, K. Shimamura, J. Kimura, I. Michishita, T. Suzuki, and R. Nagai. 2000. Circulating oxidized low density lipoprotein levels. A biochemical risk marker for coronary heart disease. Arterioscler. Thromb. Vasc. Biol. 20: 2243-2247.
27. Virella, G., S. Koskinen, G. Krings, J. M. Onorato, S. R. Thorpe, and M. Lopes-Virella. 2000. Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies. Clin. Immunol. 95:135-144.
28. Virella, G., and M. F. Lopes-Virella. 2003. Lipoprotein autoantibodies: measurement and significance. Clin. Diagn. Lab. Immunol. 10:499-505.
29. Virella, G., S. Thorpe, N. L. Alderson, M. B. Derrick, C. Chassereau, J. M. Rhett, and M. F. Lopes-Virella. 2004. Definition of the immunogenic forms of modified human LDL recognized by human autoantibodies and by rabbit hyperimmune antibodies. J. Lipid Res. 45:1859-1867.
30. Virella, G., S. R. Thorpe, N. L. Alderson, E. M. Stephan, D. H. Atchley, F. Wagner, M. F. Lopes-Virella et al. 2003. Autoimmune response to advanced glycosylation end-products of human low density lipoprotein. J. Lipid Res. 443:487-493.
31. Vlassara, H., R. Bucala, and L. Striker. 1994. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab. Investig. 70:138-151.
32. Yamazaki, K., H. Bujo, K. Taira, N. Itou, M. Shibasaki, K. Takahashi, and Y. Saito. 2004. Increased circulating malondialdehyde-modified LDL in the patients with familial combined hyperlipidemia and its relation with the hepatic lipase activity. Atherosclerosis 172:181-187.
33. Yla-Herttuala, S., W. Palinski, M. E. Rosenfeld, S. Parthasarathy, T. E. Carew, S. Butler, J. L. Witztum, and D. Steinberg. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Investig. 84:1086-1095.